NASDAQ: IRMD · Industrial Applications and Services · 3 alerts · CIK 1325618
Share price
$84.84Close, Nov 16
Market cap
$1.08B
Shares outstanding
12.79MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Iradimed Corp filings on SEC EDGAR ↗
For the nine months ended September 30, 2026, IRADIMED reported revenue of $66.6 million, a 9% increase over the prior year period. Net cash and cash equivalents grew to $63.3 million, while total stockholders' equity increased to $106.5 million from $94.6 million at the end of 2025.
Iradimed delivered record Q3 revenue driven by the 3870 pump launch, though management lowered the top-end of full-year revenue guidance due to production ramp constraints.
IRADIMED reported record Q3 2026 revenue of $24.2 million, a 14% year-over-year increase driven by the launch of its new 3870 MR IV pump. The company also declared a quarterly cash dividend of $0.20 per share and updated its full-year 2026 revenue guidance to a range of $91.6 million to $93.1 million.
Term
Q3 2026
“We are pleased to report record revenue of $24.2 million for the third quarter, driven by the continued successful launch of our new 3870 MR IV pump. As our manufacturing team gains experience with the new platform while at the same time greatly ramping up production, we began realizing the efficiencies we anticipated with gross margin improving sequentially as expected.”
Roger Susi, President and Chief Executive Officer of Iradimed
“For the fourth quarter of 2026, we expect revenue of $25.0 million to $26.5 million, attaining a $100.0 million revenue run rate while generating GAAP diluted earnings per share of $0.53 to $0.57 and non-GAAP diluted earnings per share of $0.57 to $0.61.”
Roger Susi, President and Chief Executive Officer of Iradimed